Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease

Laboratory Investigation

Volumn 92, Issue 4, 2012, Pages 488-498

  Kim, Su Hyun ^a   Yu, Min A ^b   Ryu, Eun Sun ^b   Jang, Yang Hee ^b   Kang, Duk Hee ^b  

^a Chung Ang University   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

apoptosis; chronic kidney disease; epithelial to mesenchymal transition; indoxyl sulfate; MAPKinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA SMOOTH MUSCLE ACTIN; INDICAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROBENECID; PROTEIN ZO1; UVOMORULIN;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; KIDNEY DISEASE; KIDNEY TUBULE CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ACTINS; ANIMALS; APOPTOSIS; CADHERINS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; INDICAN; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEINS; RATS; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84859321859     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.194     Document Type: Article

References (41)

1. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-1823. (Pubitemid 29364682)
2. Deguchi T, Ohtsuki S, Otagiri M, et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int 2002;61:1760-1768. (Pubitemid 34437929)
3. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994;124:96-104. (Pubitemid 2125685)
4. Taki K, Nakamura S, Miglinas M, et al. Accumulation of indoxyl sulfate in OAT1/3-positive tubular cells in kidneys of patients with chronic renal failure. J Ren Nutr 2006;16:199-203. (Pubitemid 43975010)
5. Miyazaki T, Ise M, Seo H, et al. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl 1997;62:S15-S22. (Pubitemid 27489395)
6. Niwa T, Ise M, Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994;14:207-212. (Pubitemid 24257961)
7. Niwa T, Aoyama I, Takayama F, et al. Urinary indoxyl sulfate is a clinical factor that affects the progression of renal failure. Miner Electrolyte Metab 1999;25:118-122. (Pubitemid 29196647)
8. Nakamura T, Kawagoe Y, Ueda Y, et al. Effects of oral adsorbent AST-120 in patients with chronic renal failure with or without diabetes. Ren Fail 2004;26:99-101. (Pubitemid 38435540)
9. Schulman G, Agarwal R, Acharya M, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006;47:565-577.
10. Motojima M, Hosokawa A, Yamato H, et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003;63:1671-1680. (Pubitemid 36513312)
11. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12. (Pubitemid 38020692)
12. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010;21:1247-1253.
13. Ortiz A, Lorz C, Justo P, et al. Contribution of apoptotic cell death to renal injury. J Cell Mol Med 2001;5:18-32. (Pubitemid 33773313)
14. Yu MA, Shin KS, Kim JH, et al. HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol 2009;20:567-581.
15. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:1551-1558.
16. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943. (Pubitemid 36513344)
17. Lesaffer G, De Smet R, Lameire N, et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50-57. (Pubitemid 30037930)
18. Gelasco AK, Raymond JR. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 2006;290: F1551-F1558. (Pubitemid 43830783)
19. Dou L, Jourde-Chiche N, Faure V, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007;5:1302-1308. (Pubitemid 46902134)
20. Iida S, Kohno K, Yoshimura J, et al. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Clin Exp Nephrol 2006;10: 262-267. (Pubitemid 46012955)
21. Strutz F, Muller GA, Neilson EG. Transdifferentiation: a new angle on renal fibrosis. Exp Nephrol 1996;4:267-270. (Pubitemid 26342895)
22. Ng YY, Huang TP, Yang WC, et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998;54:864-876.
23. Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002;13:96-107. (Pubitemid 34042016)
24. Acloque H, Adams MS, Fishwick K, et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009;119:1438-1449.
25. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110: 341-350. (Pubitemid 34847966)
26. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001;159:1465-1475. (Pubitemid 32947976)
27. Kim SH, Ghee JY, Piao S, et al. Early and delayed effects of AST-120 on chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011; 26:1502-1515.
28. Murcia NS, Sweeney Jr WE, Avner ED. New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 1999;55: 1187-1197. (Pubitemid 29157115)
29. Shimizu A, Masuda Y, Kitamura H, et al. Apoptosis in progressive crescentic glomerulonephritis. Lab Invest 1996;74:941-951. (Pubitemid 26152663)
30. Truong LD, Petrusevska G, Yang G, et al. Cell apoptosis and proliferation in experimental chronic obstructive uropathy. Kidney Int 1996;50:200-207. (Pubitemid 26323714)
31. Yang Y, Pan X, Lei W, et al. Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene 2006;25:7235-7244. (Pubitemid 44809089)
32. Francescato HD, Costa RS, da Silva CG, et al. Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage. Life Sci 2009;84:590-597.
33. Kwon CH, Park JY, Kim TH, et al. Ciglitazone induces apoptosis via activation of p38 MAPK and AIF nuclear translocation mediated by reactive oxygen species and Ca(2+) in opossum kidney cells. Toxicology 2009;257:1-9.
34. Kim YK, Kim HJ, Kwon CH, et al. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol 2005; 25:374-382. (Pubitemid 41337233)
35. Hashimoto S, Gon Y, Takeshita I, et al. Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 2001;163:152-157. (Pubitemid 32095266)
36. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011;6:30-39.
37. Palm F, Nangaku M, Fasching A, et al. Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. Am J Physiol Renal Physiol 2010;299: F380-F386.
38. Kawakami T, Inagi R, Wada T, et al. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol 2010;299:F568-F576.
39. Satoh M, Hayashi H, Watanabe M, et al. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol 2003;95:e111-e118.
40. Akizawa T, Asano Y, Morita S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009;54:459-467.
41. Konishi K, Nakano S, Tsuda S, et al. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 2008;81:310-315.